Androgen receptor (AR) has been considered a driver of therapeutic resistance in PC via its aberrant activation [3,4] or the presence of AR gene mutations (e.g., AR F876L) or variants (e.g., ARv567es and AR-V7) [4,5]. The gene discussed is AR; the disease is pachyonychia congenita.